Skip to main content
Fig. 3 | Cancer Imaging

Fig. 3

From: Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer

Fig. 3

Representative images. A A 47‐year‐old female patient with MHBC underwent 18F‐FDG PET/CT scan, and the lesion of largest HI is showed by the arrow, the SUVmax = 3.76, SUVmean = 2.48, HI50% = 1.516, and her PFS has not reached within 20.47 months of follow-up; B A 51‐year‐old female patient with MHBC underwent 18F‐FDG PET/CT scan, the lesion of largest HI50% is showed by the arrow, the SUVmax = 4.83, SUVmean = 3.06, HI = 1.578, and her PFS was 3.09 months

Back to article page